Format

Send to

Choose Destination
Neuro Oncol. 2019 Mar 29. pii: noz058. doi: 10.1093/neuonc/noz058. [Epub ahead of print]

EZHIP / CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.

Author information

1
Division of Pediatric Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany. (J.-M.H., M.M., S.M.P., K.W.P. and M.K.).
2
Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ), Heidelberg, Germany. (J.-M.H., M.M., S.M.P., K.W.P. and M.K.).
3
Faculty of Biosciences, Heidelberg University Germany, Heidelberg, 69120, Germany. (J.-M.H.).
4
Division Proteomics of Stem Cells and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany. (T.M. and J.K.).
5
Medical Faculty, Heidelberg University, Heidelberg, Germany. (T.M. and J.K.).
6
Heidelberg University Biochemistry Center (BZH), Im Neuenheimer Feld 328, Heidelberg 69120, Germany. (R.B.R.).
7
Bioquant, Heidelberg University, Im Neuenheimer Feld 267, Heidelberg 69120. (R.B.R.).
8
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA.
9
Department of Pediatric Oncology, Hematology and Immunology, University Hospital, 69120 Heidelberg, Germany. (S.M.P. and K.W.P.).

Abstract

BACKGROUND:

Posterior fossa A (PFA) ependymomas comprise one out of nine molecular groups of ependymoma. PFA tumors are mainly diagnosed in infants and young children, show a poor prognosis and are characterized by a lack of the repressive histone H3 lysine 27 trimethylation (H3K27me3) mark. Recently, we reported CXorf67 overexpression as hallmark of PFA ependymoma and showed that CXorf67 can interact with EZH2 thereby inhibiting polycomb repressive complex 2 (PRC2), but the mechanism of action remained unclear.

METHODS:

We performed mass spectrometry (MS) and peptide modelling analyses to identify the functional domain of CXorf67 responsible for binding and inhibition of EZH2. Our findings were validated by immunocytochemistry, western blot and methyltransferase assays.

RESULTS:

We find that the inhibitory mechanism of CXorf67 is similar as in diffuse midline gliomas harboring H3K27M mutations. A small, highly conserved peptide sequence located in the C-terminal region of CXorf67 mimics the sequence of K27M mutated histones and binds to the SET domain of EZH2. This interaction blocks EZH2 methyltransferase activity and inhibits PRC2 function causing de-repression of PRC2 target genes including genes involved in neurodevelopment.

CONCLUSIONS:

Expression of CXorf67 is an oncogenic mechanism that drives H3K27 hypomethylation in PFA tumors by mimicking K27M mutated histones. Disrupting the interaction between CXorf67 and EZH2 may serve as a novel targeted therapy for PFA tumors but also for other tumors that overexpress CXorf67. Based on its function, we have renamed CXorf67 into EZH Inhibitory Protein (EZHIP).

KEYWORDS:

EZH2; EZHIP / CXORF67; H3K27me3; PFA Ependymoma; PRC2

PMID:
30923826
DOI:
10.1093/neuonc/noz058

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center